Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Final analysis of DREAMM-3 comparing belantamab mafodotin to pom/dex in RRMM shows better median PFS (11.2 vs 7.0 mos), OS (24.0 vs 22.9 mos), DOR (25.3 vs 9.9 mos), CR & MRD- rate (8$ vs <1%), and PFS2 (17.3 vs 13.0 mos).”
Title: Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Authors: Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel
You can read the full article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
